Aravis is a Switzerland based venture capital organisation managing two funds focused on life science (Aravis Biotech I & II) and a third fund focused on renewable energy (Aravis Energy I). Since 1995 the Aravis management team have invested over $600 million in more than 80 companies.
As well as providing venture capital backing, Aravis also takes a hands-on approach to highly promising companies offering a unique international network that combines decades of experience in science, operations and financing.
Investment Focus: Bridging the gap from pre-clinic to clinic
Aravis' distinctive competence in assessing scientific risks, besides other risks, allows the selection of pre-proof of concept (i.e. platform technologies, late pre-clinical and early clinical) companies and turnaround situations offering outstanding risk-return profiles. Current investment interests focus on cross-border deals as well as companies working in the therapeutic areas of Immunology, Inflammation, Oncology and CNS.